KISS, David, Táňa MACHÁČKOVÁ, Kamila SOUČKOVÁ, Pavel FABIAN, Iveta KŘEPELKOVÁ, M. SVOBODA a Igor KISS. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. In vivo. ATHENS: Greece : International Institute of Anticancer Research, 2021, roč. 35, č. 5, s. 2809-2814. ISSN 0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.12567. |
Další formáty:
BibTeX
LaTeX
RIS
@article{1837296, author = {Kiss, David and Macháčková, Táňa and Součková, Kamila and Fabian, Pavel and Křepelková, Iveta and Svoboda, M. and Kiss, Igor}, article_location = {ATHENS}, article_number = {5}, doi = {http://dx.doi.org/10.21873/invivo.12567}, keywords = {Bevacizumab; metastatic colorectal cancer; microRNA; progression-free survival; predictive biomarker; validation}, language = {eng}, issn = {0258-851X}, journal = {In vivo}, title = {An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer}, url = {https://iv.iiarjournals.org/content/35/5/2809}, volume = {35}, year = {2021} }
TY - JOUR ID - 1837296 AU - Kiss, David - Macháčková, Táňa - Součková, Kamila - Fabian, Pavel - Křepelková, Iveta - Svoboda, M. - Kiss, Igor PY - 2021 TI - An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer JF - In vivo VL - 35 IS - 5 SP - 2809-2814 EP - 2809-2814 PB - Greece : International Institute of Anticancer Research SN - 0258851X KW - Bevacizumab KW - metastatic colorectal cancer KW - microRNA KW - progression-free survival KW - predictive biomarker KW - validation UR - https://iv.iiarjournals.org/content/35/5/2809 N2 - Background/Aim: The monoclonal antibody bevacizumab is a standard drug used in combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI) based chemotherapy in the first or second-line treatment of metastatic colorectal cancer (mCRC). Our previous study identified and subsequently validated 4 microRNAs in a small group of patients as predictors of the therapeutic response to bevacizumab combined with chemotherapy. The aim of this follow-up study is to confirm the predictive ability of these tissue miRNAs in a larger independent cohort of mCRC patients. Patients and Methods: The retrospective study included 92 patients with generalized-radically inoperable tumors treated with the combined therapy of bevacizumab/FOLFOX in a standard regimen. Results: Expression levels of candidate miRNA biomarkers (miR-92b3p, miR-3156-5p, miR-10a-5p and miR-125a-5p) were determined in tumor tissue specimens and statistically evaluated. MiR-92b-3p and miR-125a-5p were confirmed to be associated with radiological response according to RECIST criteria (p=0.005 and 0.05, respectively) and to be up-regulated in responders to bevacizumab/FOLFOX therapy. Higher levels of miR-92b-3p were also significantly associated with extended progression-free survival ER -
KISS, David, Táňa MACHÁČKOVÁ, Kamila SOUČKOVÁ, Pavel FABIAN, Iveta KŘEPELKOVÁ, M. SVOBODA a Igor KISS. An Independent Validation Study of Candidate microRNAs as Predictive Biomarkers for Bevacizumab-based Therapy in Patients With Metastatic Colorectal Cancer. \textit{In vivo}. ATHENS: Greece : International Institute of Anticancer Research, 2021, roč.~35, č.~5, s.~2809-2814. ISSN~0258-851X. Dostupné z: https://dx.doi.org/10.21873/invivo.12567.
|